Shahira M. EzzatPassent M. Abdel BakiRana M. IbrahimDoaa Abu ElezzMahmoud AbdelazizMohamed A. Salem2024-11-182024-11-182024-01-01Ezzat, S. M., Baki, P. M. A., Ibrahim, R. M., Elezz, D. A., Abdelaziz, M., & Salem, M. A. (2024). Clinical uses of cannabis and Catha edulis products. In Elsevier eBooks (pp. 595–628). https://doi.org/10.1016/b978-0-323-95927-8.00028-1https://doi.org/10.1016/b978-0-323-95927-8.00028-1https://repository.msa.edu.eg/handle/123456789/6250The medicinal use of cannabis (Cannabis sativa) and khat (Catha edulis) as well as their products has been increased in the last decade. Medical cannabis and khat have been legalized in several countries. Additionally, the major cannabinoids, particularly cannabidiol and tetrahydrocannabinol, have been utilized for the development of FDA-approved pharmaceuticals. The clinical applications of cannabis and C. edulis products are complicated by legislation and regulations that are varied among countries. In this chapter, the pharmacological and the side effect profiles for the clinical uses of cannabis and C. edulis products are highlighted. Although, the clinical data for their use are continuing to evolve, the legal status needs to be authorized to keep the balance between clinical applications and limitations.en-UScannabiscardiovascular diseasecellular processclinical history findingclinical trials side effectscognitive processcognitive psychologydrugdrug developmentKhatlegal usemedicinemental disordernervous systemnervous system disorderneuroscienceorganic compoundpainpharmaceutical therapypharmacological parameterpharmacologypharmacology disciplinepsychological disorderstherapeutic proceduretoxicityArticlehttps://doi.org/10.1016/b978-0-323-95927-8.00028-1